With trials ofSinovac Biotech Ltd.’s coronavirus vaccine in Brazil and Turkey suggesting the shot has a protection rate on either side of 90%, there is still no final assessment on exactly how effective it is in protecting people against Covid-19.
Sinovac is finalizing results of phase III trials carried out in Brazil, Turkey, Indonesia and Chile, according to a person familiar with the trials. Those tests are relatively independent from each other and conducted according to different protocols, rather than subject to unified norms that typically govern such trials, said the person, who asked not to be identified because the data isn’t public.
Researchers in Brazil earlier this weekdelayed releasing complete information on Sinovac’s vaccine, saying only that it was found to be more than 50% effective. Sao Paulo state Health Secretary Jean Gorinchteyn offered more specific guidance on Thursday, saying the vaccine “didn’t reach 90%” efficacy, which would make it less successful than those developed byPfizer Inc. andModerna Inc.
“We don’t know how much more than 50% it was, whether it was 60%, 70% or 80%, but it’s at levels that allow us to reduce the impact of the disease on our population,” Gorinchteyn said in an interview with Brazil’s CBN Radio. “We knew that the effectiveness would never reach 90%.”
228,131 in U.S.Most new cases today
+11% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23
-0.8094 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23
3.7% Global GDP Tracker (annualized), Nov.